Table 2.

Genetic alterations of type I and type II endometrial carcinomas, reported in percentages (references).

	Type I	Type II
PTEN inactivation	Up to 83% [1, 4, 11, 12]	11% [1, 2, 12]
PIK3CA mutation	26–36% [7, 9]	5% [7]
KRAS mutation	10–30% [1, 2, 4, 7–12, 17]	0–10% [2, 12]
β-catenin /CTNNB1 mutation	14–44% [7, 8]	0–5% [1, 7, 10, 11]
Microsatellite instability	20–45% [1, 7–10]	0–11% [8, 9]
p53 mutation	10–20% [1, 4, 6, 7, 10, 11, 13, 17, 18]	90% [1, 2, 4, 6, 7, 10–13, 17]
HER2/neu amplification	10–30% [1, 4, 10, 17]	18–80% [13]
p16 inactivation	10% [1, 4, 7, 10, 11]	40–45% [4, 7, 10]
E-cadherin loss	10–20% [1, 4, 7, 10, 11]	60–90% [4]